Dan Cua, PhD, Vice President, IL-23 Pathway Leader, Janssen Research & Development, LLC discusses new data showing that TREMFYA binds to both inflammatory cells and IL-23, supporting a hypothesis for a differentiated mechanism of action. These in vitro studies suggest that TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation in immune-mediated diseases like psoriasis and psoriatic arthritis. These data were presented at the Society for Investigative Dermatology (SID) 2022 Meeting.
Dan Cua, Ph.D. is Vice President, IL-23 Pathway Leader for the Immunology Therapeutic Area at Janssen Research and Development, LLC. In this role, Dan oversees the design and implementation of the scientific strategy for Discovery, Early, and Late Clinical Development of Janssen’s IL-23 pathway program. A recognized leader in the field of IL-23 biology, Dan has published more than 100 peer-reviewed articles, including the first publication on IL-23 regulation of immunity. His articles have been cited more than 41,000 times, making him one of the most cited authors in the immunology field. In addition, he holds 15 patents. Dan received his Ph.D. in Molecular Microbiology and Immunology from the University of Southern California (USC) School of Medicine. He also completed two postdoctoral fellowships at the USC Department of Neurobiology within the School of Medicine and DNAX Research Institute.